Wound Management Technologies gets clearance for its resorbable bone wax Share

It will be delivered in a unique applicator that allows surgeons to directly apply the waxy product on bleeding bones.

Wound Management Technologies (OTCQB:WNDM) announced its Resorbable Orthopedic Products (ROP) subsidiary has received FDA clearance for HemaQuell resorbable bone wax.

HemaQuell, which is based on a patent acquired in 2009, is a water soluble material used to control bleeding from bone surfaces.

Advertisement

It will be delivered in a unique applicator that allows surgeons to directly apply the waxy product on bleeding bones.

Unlike other non-resorbable “bone wax” the HemaQuell material is completely resorbed (re-absorbed) harmlessly into the body within a week and does not delay healing of bone injury.

Deborah Hutchinson, president of Wound Management Technologies, said: “We are extremely pleased to have this approval for HemaQuell.”

“HemaQuell will generate additional sales opportunities for our company in the operating room,” she added.

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement